New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.

@article{Sahebkar2014NewPP,
  title={New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.},
  author={Amir Hossein Sahebkar and Gerard Chew and Gerald F. M. Watts},
  journal={Expert opinion on pharmacotherapy},
  year={2014},
  volume={15 4},
  pages={
          493-503
        }
}
INTRODUCTION Novel peroxisome proliferator-activated receptor (PPAR) modulators (selective PPAR modulators [SPPARMs]) and dual PPAR agonists may have an important role in the treatment of cardiometabolic disorders owing to lipid-modifying, insulin-sensitizing and anti-inflammatory effects. AREAS COVERED This review summarizes the efficacy of new PPAR agonists and SPPARMs that are under development for the treatment of atherogenic dyslipidemia and non-alcoholic fatty liver disease (NAFLD… CONTINUE READING
Highly Cited
This paper has 80 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Exercise Mimetics: Impact on Health and Performance.

Cell metabolism • 2017
View 4 Excerpts
Highly Influenced

PPAR Agonists and Metabolic Syndrome: An Established Role?

International journal of molecular sciences • 2018
View 1 Excerpt

81 Citations

0102030'14'15'16'17'18'19
Citations per Year
Semantic Scholar estimates that this publication has 81 citations based on the available data.

See our FAQ for additional information.